By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#133 - Vinay Prasad, M.D., M.P.H: Hallmarks of successful cancer policy
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Vinay Prasad Lays Out Six Hallmarks for Fixing Cancer Policy
- Prasad traces his path from philosophy major to oncologist and health policy researcher, driven by seeing clinical practices like stenting for stable angina that conflicted with the evidence he read.
- He explains medical reversal, where widely adopted practices such as hormone therapy and PVC-suppressing drugs were later overturned by rigorous randomized trials.
- He argues oncology suffers from high costs for small gains, drug trials in unrepresentative fit patients, surrogate endpoints like tumor shrinkage and progression-free survival, and a payment system that insulates decision makers from cost.
- He proposes six hallmarks of cancer policy: independence, evidence, relevance, affordability, possibility and agenda, covering conflicts of interest, patient-relevant endpoints, real-world trial populations, Medicare pricing, basic science funding and trial redundancy.
- In the closing sections, he gives a measured view of tumor sequencing and liquid biopsies and describes a clinical philosophy of balancing skepticism with practicing under imperfect information.
IDEAS WORTH REMEMBERING
5 ideasWidely adopted practices can turn out to be harmful or useless.
Prasad cites hormone replacement therapy and the CAST trial of PVC-suppressing drugs, where plausible mechanisms and observational data were overturned by randomized trials.
Gratitude plus payment makes procedures hard to abandon.
Prasad says patient thanks combined with financial reward is like 'the methamphetamine of being a doctor,' which is why the ORBITA sham-controlled stent result is so hard for cardiologists to accept.
Average cancer drug benefits are modest and often shrink in real-world patients.
He cites an average gain of 2.1 months across 71 solid tumor drugs and the sorafenib example, where trial patients lived about 11 months versus about four in Medicare patients, no better than those not taking the drug.
Tumor shrinkage and progression-free survival are weak stand-ins for living longer or better.
Prasad notes that only about a third of approved cancer drugs show survival or quality-of-life benefit, and the 30% shrinkage cutoff traces back to a 1976 study of doctors measuring marbles.
Financial conflicts are most concerning among senior oncologists who write guidelines.
He says the pens and meals matter less than six-figure consulting payments to those whose guidelines force Medicare to pay for drugs, and he favors changing incentives over banning or relying on disclosure.
WORDS WORTH SAVING
5 quotesWhen you combine that powerful psychological stimulus of gratitude with a little bit of financial remuneration, I think that's the methamphetamine of being a doctor.
— Vinay Prasad
There's a Coca-Cola and there's a Pepsi-Cola, and we're getting lots of Pepsi-Colas. We're getting a lot of me-too drugs.
— Vinay Prasad
In the U.S., we do ration. We just ration in a way you don't see because some people don't get anything.
— Vinay Prasad
It's not the doctor's role to determine what treatment is right for someone. It's really the doctor's role, in my mind, to empower the patient with what I know about the drug, what's been shown, what hasn't been shown, what the benefit might be, what are the uncertainties, what are the known toxicities and risks.
— Vinay Prasad
If I tell you you're really hungry and you can only eat 20% of the pizza, what size pizza should I order? The answer's gonna be extra large.
— Vinay Prasad
High quality AI-generated summary created from speaker-labeled transcript.
